These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

802 related articles for article (PubMed ID: 19384567)

  • 1. Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease by blocking microglial activation.
    Moon M; Kim HG; Hwang L; Seo JH; Kim S; Hwang S; Kim S; Lee D; Chung H; Oh MS; Lee KT; Park S
    Neurotox Res; 2009 May; 15(4):332-47. PubMed ID: 19384567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
    Kim S; Moon M; Park S
    J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ghrelin antagonizes MPTP-induced neurotoxicity to the dopaminergic neurons in mouse substantia nigra.
    Jiang H; Li LJ; Wang J; Xie JX
    Exp Neurol; 2008 Aug; 212(2):532-7. PubMed ID: 18577498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson's disease by blocking microglial activation.
    Delgado M; Ganea D
    FASEB J; 2003 May; 17(8):944-6. PubMed ID: 12626429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    L'Episcopo F; Tirolo C; Caniglia S; Testa N; Serra PA; Impagnatiello F; Morale MC; Marchetti B
    J Neuroinflammation; 2010 Nov; 7():83. PubMed ID: 21092260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.
    Wu DC; Jackson-Lewis V; Vila M; Tieu K; Teismann P; Vadseth C; Choi DK; Ischiropoulos H; Przedborski S
    J Neurosci; 2002 Mar; 22(5):1763-71. PubMed ID: 11880505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Harpagoside attenuates MPTP/MPP⁺ induced dopaminergic neurodegeneration and movement disorder via elevating glial cell line-derived neurotrophic factor.
    Sun X; Xiong Z; Zhang Y; Meng Y; Xu G; Xia Z; Li J; Zhang R; Ke Z; Xia Z; Hu Y
    J Neurochem; 2012 Mar; 120(6):1072-83. PubMed ID: 22192054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation.
    Chung YC; Kim SR; Park JY; Chung ES; Park KW; Won SY; Bok E; Jin M; Park ES; Yoon SH; Ko HW; Kim YS; Jin BK
    Neuropharmacology; 2011 May; 60(6):963-74. PubMed ID: 21288472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tanshinone I selectively suppresses pro-inflammatory genes expression in activated microglia and prevents nigrostriatal dopaminergic neurodegeneration in a mouse model of Parkinson's disease.
    Wang S; Jing H; Yang H; Liu Z; Guo H; Chai L; Hu L
    J Ethnopharmacol; 2015 Apr; 164():247-55. PubMed ID: 25666429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-17A exacerbates neuroinflammation and neurodegeneration by activating microglia in rodent models of Parkinson's disease.
    Liu Z; Qiu AW; Huang Y; Yang Y; Chen JN; Gu TT; Cao BB; Qiu YH; Peng YP
    Brain Behav Immun; 2019 Oct; 81():630-645. PubMed ID: 31351185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor-alpha.
    Sriram K; Miller DB; O'Callaghan JP
    J Neurochem; 2006 Feb; 96(3):706-18. PubMed ID: 16405514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum.
    Kawasaki T; Ishihara K; Ago Y; Baba A; Matsuda T
    J Pharmacol Exp Ther; 2007 Jul; 322(1):274-81. PubMed ID: 17429058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic changes in pro- and anti-inflammatory cytokines in microglia after PPAR-γ agonist neuroprotective treatment in the MPTPp mouse model of progressive Parkinson's disease.
    Pisanu A; Lecca D; Mulas G; Wardas J; Simbula G; Spiga S; Carta AR
    Neurobiol Dis; 2014 Nov; 71():280-91. PubMed ID: 25134730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity.
    Zhang D; Hu X; Wei SJ; Liu J; Gao H; Qian L; Wilson B; Liu G; Hong JS
    J Neuroinflammation; 2008 May; 5():21. PubMed ID: 18507839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iptakalim protects against MPP+-induced degeneration of dopaminergic neurons in association with astrocyte activation.
    Yang YJ; Zhang S; Ding JH; Zhou F; Hu G
    Int J Neuropsychopharmacol; 2009 Apr; 12(3):317-27. PubMed ID: 18700057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenuigenin protects dopaminergic neurons from inflammation via suppressing NLRP3 inflammasome activation in microglia.
    Fan Z; Liang Z; Yang H; Pan Y; Zheng Y; Wang X
    J Neuroinflammation; 2017 Dec; 14(1):256. PubMed ID: 29262843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
    Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
    Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FTY720 Inhibits MPP
    Yao S; Li L; Sun X; Hua J; Zhang K; Hao L; Liu L; Shi D; Zhou H
    J Neuroimmune Pharmacol; 2019 Sep; 14(3):478-492. PubMed ID: 31069623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson's disease.
    Ghosh A; Kanthasamy A; Joseph J; Anantharam V; Srivastava P; Dranka BP; Kalyanaraman B; Kanthasamy AG
    J Neuroinflammation; 2012 Oct; 9():241. PubMed ID: 23092448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SEA0400, a specific Na+/Ca2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease.
    Ago Y; Kawasaki T; Nashida T; Ota Y; Cong Y; Kitamoto M; Takahashi T; Takuma K; Matsuda T
    Neuropharmacology; 2011 Dec; 61(8):1441-51. PubMed ID: 21903118
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.